Furthermore, allogeneic stem cell transplantation, in whichpatients receive stem cells from a related or unrelated donor, may increaseresponse times for selected younger patients whose disease has relapsed (returned after treatment).
Reduced-intensity transplants called non-myeloablative or mini-transplants are procedures in which stem cells are received from an allogeneic donor, but the chemotherapy or radiation administered prior to the transplant is less intense (i.e., just enough to allow the body to accept the donor cells).
The transplanted cells recognize the cancer as a foreign invader and activate immune cells to destroy it. Patients receiving reduced-intensity transplants may avoid some of the side effects seen with high-dose chemotherapy coupled with fully ablative allogeneic SCT.
Get in-depth information about Mantle Cell Lymphoma Market Forecast
The dynamics of MCL market is anticipated to change in thecoming years owing to the improvement in the diagnosis methodologies, risingawareness of the diseases, incremental healthcare spending across the world and expected launch of emerging therapies during the forecast period of 2022–2032.
Companies across the globe are working towards the development of new treatment therapies for mantle cell lymphoma. As per the new NICE guidance issued in January 2021, proposedthe treatment with Tecartus can be considered for those with relapsed orrefractory MCL, who must previously have had a drug called BTK inhibitor, such as ibrutinib.
NICE has agreed a managed access agreement with manufacturer Kite –a Gilead company – so more data can be collected while patients can access the treatment. In addition to this, in order to make Velcade accessible tomore patients, Takeda is conducting Velcade Reimbursement Assistance program(VRAP). This program provides Velcade at no cost to the patients.
This is a temporary assistance program that looks at patient’s financial and medical needs. Patient will not need to pay any co-pays or enrollment feesto get help from this program. Once enrolled, you will receive a supply of themedication in the amount needed for your treatment or as determined by the program. In addition, the program will work with you and/or your physician to determine where your medication will be shipped.
Read More- Mantle Cell Lymphoma Treatment Market
